Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses PD-L1 as a biomarker in lung cancer.
PD-L1 has had ups and downs as a biomarker, says Gandara. It seemed promising early on, but after data with nivolumab (Opdivo) came out in non-small cell lung cancer, it was no longer seen as a specific indicator.
Gandara adds that the field is still grasping for the best biomarkers to use in this disease.
